Skip to main content
Lyra Therapeutics, Inc. logo

Lyra Therapeutics, Inc. — Investor Relations & Filings

Ticker · LYRA ISIN · US55234L1052 US Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2026-04-20 Delisting Announcement
Country US United States of America
Listing US LYRA

About Lyra Therapeutics, Inc.

https://lyratherapeutics.com/

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company that develops and commercializes innovative therapies for the localized treatment of chronic rhinosinusitis (CRS). The company's product candidates are long-acting, anti-inflammatory sinonasal implants designed to deliver medication directly to sinonasal tissues. This approach aims to provide a new, long-lasting treatment option for patients with this debilitating inflammatory disease, targeting tissues that are not easily accessible with conventional therapeutic methods.

Recent filings

Filing Released Lang Actions
25 - Lyra Therapeutics, Inc. (0001327273) (Filer)
Delisting Announcement
2026-04-20 English
8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the termination of a material definitive agreement related to a sublease, including financial terms and obligations. It does not contain financial statements or detailed financial performance data, nor is it an earnings release or annual/interim report. It is not a proxy, voting result, or management change announcement. The document is a regulatory announcement of a material event, fitting the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories. The document length is short (3275 characters), and it is not an announcement of a report publication but a standalone event disclosure. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2026-04-17 English
8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 31, 2026. It reports the termination of two material lease agreements by Lyra Therapeutics, Inc., including details of lease termination payments and security deposit forfeitures. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The content is an update on a material definitive agreement termination, which is typically reported via Form 8-K. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about a material contract termination and does not fit other more specific categories like Annual Report, Interim Report, or Capital Update. The document length is under 5,000 characters and is a standalone announcement, not a report publication notice or certification. Therefore, the classification is RNS with high confidence.
2026-04-10 English
10-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
Annual Report FY 2025
2026-03-31 English
EFFECT - Lyra Therapeutics, Inc. (0001327273) (Filer)
Regulatory Filings
2026-03-27 English
EFFECT - Lyra Therapeutics, Inc. (0001327273) (Filer)
Regulatory Filings
2026-03-27 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.